$0.04
30.91% yesterday
Nasdaq, Nov 25, 03:30 pm CET
ISIN
US0787711029
Symbol
BLPH

Bellerophon Therapeutics, Inc. Stock price

$0.06
+0.02 52.78% 1M
-0.00 2.65% 6M
+0.02 48.65% YTD
+0.02 66.67% 1Y
-3.32 98.37% 3Y
-5.71 99.05% 5Y
-134.50 99.96% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US0787711029
Symbol
BLPH
Sector

Key metrics

Market capitalization $670.00k
Enterprise Value $-3.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.31
EV/Sales (TTM) EV/Sales -0.68
P/S ratio (TTM) P/S ratio 0.12
P/B ratio (TTM) P/B ratio 0.18
Revenue (TTM) Revenue $5.64m
EBIT (operating result TTM) EBIT $-9.74m
Free Cash Flow (TTM) Free Cash Flow $-12.34m
Cash position $4.49m
EPS (TTM) EPS $-0.83
Short interest 0.90%
Show more

Is Bellerophon Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Bellerophon Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Bellerophon Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Bellerophon Therapeutics, Inc.:

Buy
100%

Financial data from Bellerophon Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
5.64 5.64
-
100%
- Direct Costs 0.01 0.01
88% 88%
0%
5.63 5.63
7,138% 7,138%
100%
- Selling and Administrative Expenses 5.66 5.66
0% 0%
100%
- Research and Development Expense 9.70 9.70
38% 38%
172%
-9.73 -9.73
55% 55%
-173%
- Depreciation and Amortization 0.01 0.01
88% 88%
0%
EBIT (Operating Income) EBIT -9.74 -9.74
55% 55%
-173%
Net Profit -9.25 -9.25
52% 52%
-164%

In millions USD.

Don't miss a Thing! We will send you all news about Bellerophon Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.

Head office United States
CEO Craig Jalbert
Founded 2009
Website www.bellerophon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today